Monthly Archives September 2016

The following products are being reference priced from 1 November 2016, which comes about from an alternative being award the Sole Supply within the next few months. With price support from the suppliers ProPharma / PWR will be reducing the pricing to match the new subsidy from 13 October 2016. We are highlighting these so that you have time to…

Pharmac recently awarded HML to Midazolam-Claris at a substantially lower price than the currently listed Hypnovel and Midazolam-Pfizer, both of which will be delisted from the HML 1 December 2016 . There is also a proposal before the board to list the Midazolam-Claris in Section B for 1 December 2016. That is yet to be considered, but we believe will…

There is an issue with the supply of the above mentioned product. It is supposedly short term, however Pharmac are enacting Rule 4.5 1b “Frequent dispensing for Pharmaceutical Supply Management” Click here to read actual Pharmac notification. The supply issue already exists. There are very limited stocks available. Please do not be offended if we are unable to supply. We…

We are all aware there are supply issues with Stelazine Tab 1 mg, 2 mg and 5 mg.  The issue is not only supply, but dating on product that is available. Stelazine Tab 1 mg 100 are not available and no ETA. However a replacement has been sourced by the supplier as follows Trifluoperazine-AMCo Tab 1 mg 112 – Section…

Please note that following this announcement ProPharma / PWR have sought price support from both Tolmar and AbbVie should the companies reduce the pricing to the reference price. Unfortunately only AbbVie have agreed and therefore we will continue to stock and supply Lucrin Depot with absolute surety of supply and support. Tolmar have declined and therefore we are advising that…

AFT have been awarded HSS for Midazolam-Claris Injection 1 mg per ml, 5 ml 10 and 5 mg per ml, 3 ml 5 both glass ampoules from 1 December 2016. Click here to read current supply status for the new product. Pharmacy must note that this listing does not impact at all on the current Pharmaceutical Schedule Section B listings.…

Effective from 1 August 2016 Pharmac have listed and fully funded Betaloc CR Tab 47.5mg and 95 mg 30 pack. This is in an effort to ensure continuity of supply and will be available, fully funded until the existing stock at AstraZeneca has moved through the supply chain including pharmacy.  The initial amount of stock available was approximately 3 months…

12
Close